Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24126317 | 0.68 | HPGD (0.36) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL24126892 | 0.64 | L3MBTL1 (0.36) | ALDH1A1 | |
| SCHEMBL17403519 | 0.63 | ALDH1A1 (0.40) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL12237556 | 0.63 | ATAD2 (0.52) | ALDH1A1GAA | |
| SCHEMBL29331830 | 0.63 | KDM4E (0.55) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL14872275 | 0.63 | KDM4E (0.79) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL31036419 | 0.61 | DAO (0.42) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL1106199 | 0.61 | ADRA1A (0.35) | KDM4EALDH1A1DAO | |
| SCHEMBL18689585 | 0.61 | KDM3B (0.46) | KDM4EALDH1A1GAA | |
| SCHEMBL21590039 | 0.61 | ALDH1A1 (0.41) | KDM4EALDH1A1GLAGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210393623-A1 | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors | JACOBIO PHARMACEUTICALS CO LTD (CN) | 2021-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393623-A1 | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors | PTPN1, PTPN5, PTPN2 | KDM4E 703/4885ALDH1A1 2966/4885GLA 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.